And there was significant difference between the ABZI and the BCP NPs + ABZI treated group, which demonstrated that the BCP NPs can enhance the immune activation ability of ABZI agonist, so as to enhance the anti-tumor effect (Fig. 7g–f). The gene discussed is OPN1SW; the disease is neoplasm.